We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19

By LabMedica International staff writers
Posted on 29 Sep 2021

NGeneBio (Seoul, Korea) showcased its next-generation sequencing (NGS)-based oncology/genetic diseases kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021. More...

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

At AACC 2021, NGeneBio showcased its NGS-based oncology/genetic diseases kits (BRCA/HEME/SOLID/ONCO/HLA). NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is intended for breast and ovarian cancer patients, HBOC (Hereditary breast and ovarian cancer syndrome) patients, and for family history or the age of breast cancer incidence.

Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetic test of multiple genes related hematologic malignancy; SOLIDaccuTest to explorer variants associated with solid tumors using a comprehensive method of NGS; HLAaccuTest All which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive solid tumor oncology NGS test.

In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of the genetic testing data produced by NGS and helps to report in clinical-grade for oncology test, alongside the EasyHLAanalyzer which provides the HLA typing identifying human leukocyte antigen for histocompatibility antigens using data from NGS. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit which is a reagent of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19.

Related Links:
NGeneBio 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.